Stock PARN.F PARNELL PHARMACEUTICALS HOLDINGS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Parnell Pharmaceuticals Holdings Ltd

Equities

PARN.F

AU0000XINEU9

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 11:07:19 2023-12-22 am EST 		5-day change 1st Jan Change
0.000001 USD -99.00% Intraday chart for Parnell Pharmaceuticals Holdings Ltd -.--% -.--%
2022 Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
2021 DW Healthcare Partners V, L.P. managed by DW Healthcare Partners completed the acquisition of a 29% stake in Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $2.5 million CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 16.02 13.85 4.038 2.955 9.149 0.004085
Enterprise Value (EV) 1 38.75 43.66 44.68 53.51 65.31 58.9
P/E ratio -0.7 x -0.6 x 31.2 x -0.41 x -0.56 x -0 x
Yield - - - - - -
Capitalization / Revenue 0.8 x 0.7 x 0.15 x 0.1 x 0.3 x 0 x
EV / Revenue 1.93 x 2.21 x 1.67 x 1.85 x 2.18 x 1.72 x
EV / EBITDA -2.55 x -4.31 x 7.94 x 22.3 x 15.4 x 9.81 x
EV / FCF -4.41 x -5.4 x -12.4 x 145 x -12.8 x -55.7 x
FCF Yield -22.7% -18.5% -8.1% 0.69% -7.82% -1.79%
Price to Book 2.16 x -1.22 x -0.22 x -0.11 x -0.3 x -0 x
Nbr of stocks (in thousands) 16,716 18,028 18,024 18,024 19,996 29,620
Reference price 2 0.9584 0.7684 0.2240 0.1639 0.4575 0.000138
Announcement Date 3/31/17 4/30/19 4/30/19 1/21/21 7/14/21 6/21/22
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales 1 20.05 19.8 26.7 28.99 30 34.17
EBITDA 1 -15.18 -10.12 5.628 2.399 4.229 6.002
EBIT 1 -16.28 -11.13 4.005 1.363 3.778 4.178
Operating Margin -81.16% -56.21% 15% 4.7% 12.59% 12.23%
Earnings before Tax (EBT) 1 -21.68 -23.12 0.337 -6.949 -15.05 -1.419
Net income 1 -21.69 -23.13 0.1296 -7.182 -15.06 -1.42
Net margin -108.16% -116.83% 0.49% -24.77% -50.2% -4.16%
EPS 2 -1.372 -1.275 0.007190 -0.3985 -0.8119 -0.0490
Free Cash Flow 1 -8.794 -8.083 -3.617 0.3684 -5.106 -1.057
FCF margin -43.85% -40.83% -13.55% 1.27% -17.02% -3.09%
FCF Conversion (EBITDA) - - - 15.36% - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/31/17 4/30/19 4/30/19 1/21/21 7/14/21 6/21/22
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 22.7 29.8 40.6 50.6 56.2 58.9
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -1.497 x -2.945 x 7.221 x 21.08 x 13.28 x 9.812 x
Free Cash Flow 1 -8.79 -8.08 -3.62 0.37 -5.11 -1.06
ROE (net income / shareholders' equity) -153% 1,422% -0.87% 32.1% 51.9% 4.26%
ROA (Net income/ Total Assets) -21.7% -17.9% 7.86% 2.35% 5.93% 6.47%
Assets 1 99.99 129.3 1.649 -305.6 -253.9 -21.93
Book Value Per Share 2 0.4400 -0.6300 -1.030 -1.460 -1.510 -1.170
Cash Flow per Share 2 0.3900 0.1300 0.2400 0.2500 0.1900 0.1500
Capex 1 0.56 0.52 1.05 0.83 0.74 0.89
Capex / Sales 2.77% 2.6% 3.93% 2.86% 2.45% 2.61%
Announcement Date 3/31/17 4/30/19 4/30/19 1/21/21 7/14/21 6/21/22
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Veterinary Drugs

1st Jan change Capi.
PARNELL PHARMACEUTICALS HOLDINGS LTD Stock Parnell Pharmaceuticals Holdings Ltd
-.--% 29
ZOETIS INC. Stock Zoetis Inc.
-19.73% 72.39B
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-11.01% 6.54B
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+15.88% 3.43B
VIMIAN GROUP AB Stock Vimian Group AB
-0.68% 1.4B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-17.27% 1.34B
VETOQUINOL SA Stock Vetoquinol SA
-2.73% 1.26B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-28.16% 1.2B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-14.67% 1.12B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-5.37% 990M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. PARN.F Stock
  4. Financials Parnell Pharmaceuticals Holdings Ltd